Skip to main content
Oramed Pharmaceuticals (ORMP) Stock Surges on $50 Million Chinese Licensing Deal

Oramed Pharmaceuticals (ORMP) Stock Surges on $50 Million Chinese Licensing Deal

Oramed Pharmaceuticals (ORMP) stock is rising on heavy volume trading on Monday after the clinical-stage pharmaceutical company announced a $50 million licensing deal in China.

Oramed Pharmaceuticals (ORMP) stock is rising on heavy volume trading on Monday after the clinical-stage pharmaceutical company announced a $50 million licensing deal in China.

NEW YORK (TheStreet) -- Oramed Pharmaceuticals  (ORMP) stock is soaring 22.95% to $9.59 on heavy volume trading on Monday, after the clinical-stage pharmaceutical company announced a $50 million licensing deal in China. 

The Jerusalem-based company focuses on the development of oral drug delivery systems for diseases such as diabetes. Oramed signed the agreement with Hefei Tianhui Incubator of Technologies Co.

The agreement gives Hefei the exclusive rights to market Oramed's oral insulin capsule in China, Hong Kong and Macau, according to a statement on Monday.

So far today, 1.8 million shares of Oramed have traded, versus its 30-day average of 79,000 shares.

Image placeholder title

ORMP

data by

YCharts

Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of Jim Cramer, TheStreet or any of its contributors.